本报讯 （记者袁传玺）11月19日，京东健康与杭州民生健康药业股份有限公司（以下简称"杭州民生健康药业"）签署战略 合作协议。双方将充分发挥各自在品牌、产品、渠道、技术和专业服务等领域的优势，共同探索构建以患者为中心的、覆盖疾 病全周期的健康管理解决方案。 近年来，随着戒烟相关药品用户规模逐年增长，京东健康携手行业伙伴构建成熟的新药首发上市解决方案，有力推动戒烟 类新药的拓展和普及，并通过全渠道业务布局，帮助县域及以下用户和偏远地区患者轻松购药。针对戒烟用户普遍存在的认知 不足、预防滞后、诊疗不便、管理缺失等痛点，京东健康能够提供多样化的解决方案，包括推出"控烟健康中心"、联合北京控 烟协会设立"戒烟门诊"等方式，实现对有控烟需求的用户的长期闭环管理，助力用户控烟成功率。今年5月，京东健康还成功 举办第一届戒烟行业论坛。 11月20日，杭州民生健康药业旗下戒烟新药酒石酸伐尼克兰片（商品名：民生乐速克®）在京东健康首发。据了解，民生 乐速克®采用0.5mg小剂量迷你药片设计，便于剂量调整与吞咽，尤其适合老年及敏感人群。包装采用先进双铝密封技术，防 潮、防氧化，确保药物活性稳定；药板设有易撕刻度与日用标识，帮助患 ...

Core Viewpoint - The article highlights the insufficient public awareness of scientific smoking cessation methods, particularly regarding cessation medications, despite the existence of effective options and guidelines from WHO [1][12]. Group 1: Smoking Cessation Medications - WHO's first clinical treatment guideline for adult smoking cessation identifies three main types of medications: varenicline, nicotine replacement therapy (NRT), and bupropion [1][12]. - Varenicline is a first-line medication with four domestic companies having approved generic versions, yet sales were below 100 million yuan last year [1][12]. - The sales of varenicline in China have not met expectations, with Pfizer's original product experiencing a significant decline due to safety concerns [1][18]. Group 2: Challenges in Smoking Cessation - Nearly 60% of smokers abandon cessation attempts due to withdrawal symptoms, with a success rate of less than 5% for those relying solely on willpower [7][8]. - The understanding of cessation medications among both smokers and healthcare professionals remains limited, contributing to low utilization rates [13][17]. - The lack of awareness and the absence of these medications in insurance coverage are identified as major barriers to effective smoking cessation [20]. Group 3: Market Trends and Opportunities - The retail market for varenicline is projected to grow significantly, with sales expected to reach 48 million yuan in 2024, reflecting a growth rate exceeding 2000% [20][21]. - Online platforms like JD Health report a more than twofold increase in sales of smoking cessation medications, indicating a shift towards digital health solutions [20]. - The market share of companies like Qianyuan Pharmaceutical in the retail sector is notably high, suggesting potential for further expansion in the smoking cessation market [20][21].

Core Viewpoint - The article highlights the challenges of quitting smoking in China, emphasizing the need for scientific methods and professional support to improve cessation success rates [1][2][3]. Group 1: Smoking Statistics and Challenges - The smoking rate among individuals aged 15 and above in China is reported at 23.2% [1]. - The success rate for individuals attempting to quit smoking on their own is less than 5% within a year [2]. - Nicotine addiction is recognized as a chronic disease, complicating the quitting process due to withdrawal symptoms such as anxiety and depression [2][3]. Group 2: Scientific Approaches to Quitting - A significant portion of smokers (87.1%) attempts to quit using nicotine replacement therapies like patches and gum, yet the usage rate of cessation medications is below 5% [3]. - The "2025 Tobacco Control and Cessation White Paper" outlines seven effective strategies for quitting smoking, including setting a quit plan and seeking professional help [3]. - The need for a collaborative effort from various sectors to provide effective health management solutions for smokers is emphasized [4]. Group 3: Industry Initiatives - JD Health, in collaboration with pharmaceutical companies, is advocating for a scientific smoking cessation management ecosystem to address public awareness and accessibility issues [4]. - The initiative includes organizing public lectures and health consultations to enhance understanding of smoking cessation [4].